Inhibition of mir-224-5p by Targeting PTX3 Promotes Inflammatory Damage in Neonatal Pneumonia

Area of Science:

• Molecular Biology
• Neonatal Medicine
• Biochemistry

Background:

• Neonatal pneumonia (NP) is a critical neonatal infection.
• Understanding NP's molecular mechanisms is crucial for diagnosis and treatment.
• miR-224-5p is investigated for its role in NP.

Purpose of the Study:

• To evaluate the diagnostic value of miR-224-5p in neonatal pneumonia.
• To elucidate the molecular mechanisms of miR-224-5p in NP.
• To identify potential therapeutic targets for NP.

Main Methods:

• Quantitative real-time PCR (RT-qPCR) to detect miR-224-5p levels.
• Cell transfection to overexpress or inhibit miR-224-5p in a lung cell model (WI38 cells) stimulated with lipopolysaccharide (LPS).
• Bioinformatics analysis, dual luciferase assays, CCK-8 assays, flow cytometry, and ELISA to assess target interaction, cell viability, apoptosis, and inflammatory cytokine levels.

Main Results:

• Plasma miR-224-5p was significantly downregulated in NP patients, demonstrating high diagnostic accuracy (AUC = 0.877).
• miR-224-5p levels correlated with clinical indicators of NP.
• In an NP model, miR-224-5p enhanced cell viability, reduced apoptosis, and mitigated inflammatory responses.
• PTX3 was identified as a potential downstream target of miR-224-5p.
• PTX3 partially reversed the anti-inflammatory effects of miR-224-5p in NP.

Conclusions:

• miR-224-5p exhibits promising diagnostic potential for neonatal pneumonia.
• miR-224-5p plays a role in regulating inflammatory responses in NP, potentially through targeting PTX3.
• Further research into miR-224-5p and PTX3 could lead to novel diagnostic and therapeutic strategies for NP.